IQVIA Holdings Inc. $IQV Shares Sold by Exencial Wealth Advisors LLC

Key Points

• Exencial Wealth Advisors LLC cut its stake in IQVIA Holdings Inc. by 5.0%, now holding 40,511 shares valued at approximately $6.38 million.
• Analysts have set a new average price target of $234.57 for IQVIA, with most ratings reflected as Moderate Buy.
• IQVIA reported a 5.3% year-over-year revenue increase, achieving $4.02 billion for the quarter, surpassing analyst estimates.

Exencial Wealth Advisors LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,511 shares of the medical research company's stock after selling 2,147 shares during the quarter. Exencial Wealth Advisors LLC's holdings in IQVIA were worth $6,384,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Clal Insurance Enterprises Holdings Ltd raised its stake in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC raised its stake in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter valued at approximately $39,000. Finally, J.Safra Asset Management Corp raised its stake in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company's stock valued at $39,000 after buying an additional 169 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Barclays upped their price objective on IQVIA from $185.00 to $200.00 and gave the company an "equal weight" rating in a research note on Thursday, October 2nd. Hsbc Global Res upgraded IQVIA from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 9th. UBS Group upped their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Robert W. Baird upped their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $234.57.

IQVIA Stock Up 3.3%

NYSE:IQV opened at $218.96 on Wednesday. The firm has a market capitalization of $37.22 billion, a PE ratio of 31.69, a price-to-earnings-growth ratio of 2.33 and a beta of 1.32. The stock has a 50 day moving average of $192.71 and a 200-day moving average of $169.95. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $231.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the company posted $2.64 EPS. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.